MNV-201
Phase 2Biologic
MNV-201 is one of 3 biologic programs targeting Mitochondria. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in Mitochondria
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Phase 2
MNV-201
MMinovia Therapeutics Ltd.
Phase 2
Acipimox
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MNV-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- MMinovia Therapeutics Ltd.